Introduction to Antibody Discovery for Immunotherapy by Premade Antibody Library

As biotechnology has evolved, the development of immunotherapy has gone through its ups and downs. From the rabies vaccine for rabies to tuberculin therapy to bacteria for chronic bacterial infections, immunotherapy has evolved and expanded its definition and meaning. The discovery of hybridoma technology led to a boom in the field of antibodies, and scientists are discovering that antibodies also play an important role in immunotherapy. Current research has shown that antibodies are effective in the treatment of various tumors, viral infections, and autoimmune diseases. This discovery once again expands the scope of immunotherapy. As the research progresses, the discovery of disease-specific antibodies becomes more important, such as anti-disease-specific target antibody and coronavirus (COVID-19) antibody discovery. Based on our rich field experience and advanced research platform, Creative Biolabs provides comprehensive services to support premade antibody library screening and antibody discovery for immunotherapy.

Antibody Discovery for Immunotherapy

Immunotherapy has played a significant therapeutic role in the treatment of different diseases, including but not limited to tumors, autoimmune diseases, and viral infections. Immunotherapy is particularly widely used in the field of tumor therapy. In view of the rapid development of immunology and protein engineering technology, monoclonal antibody immunotherapy is currently the fastest growing immunotherapy. Antibody-based immunotherapy has exerted significant therapeutic effects in the field of tumor treatment. Monoclonal antibody-based drugs can recruit T cells to the tumor site, directly targeting tumor cells and altering the host's response to the tumor, thus inhibiting or even eliminating the tumor. Monoclonal antibodies include the Fab end, which binds to tumor antigens, and the Fc end, which binds to immune cell surface receptors. Under the action of monoclonal antibodies, the binding of the two cells will kill tumor cells through complement-mediated cytotoxicity and antibody-dependent cytotoxicity. In addition, some monoclonal antibodies could exert anti-tumor effects by inhibiting tumor angiogenesis and suppressing oxygen supply and nutrient delivery to tumor cells. Another type of monoclonal antibody-based therapy, antibody-drug couplers, are targeted biologics that are coupled to highly cytotoxic drugs through a specific linker that specifically binds to tumor surface antigens, releasing the drug to kill tumor cells and activate the immune system through a "self-immolation" mechanism.

Immune checkpoints are protective factors in the body's immune system that prevent over-activation of T cells, leading to autoimmune damage. In layman's terms, when a tumor cell is produced in the body, the powerful immune system should recognize and attack it, but since immune cells produce small molecules of proteins that inhibit themselves, such molecules will ensure that the normal organism is not mistakenly injured by the immune system. However, tumor cells may use these checkpoints to evade the body's immune surveillance and killing, thus immune escape occuring. Immune checkpoint inhibitors can effectively restore T cell function by blocking immune checkpoints. Essentially different from traditional anti-tumor drugs, immune checkpoint inhibitors do not target tumor cells to kill them directly but aim to regulate our own immune function by changing the intrinsic connection between immune cells and tumor cells, altering the microenvironment of tumor cells, stimulating the immune cells to attack the tumor's great potential, and killing tumors with the help of our own immune cells, so as to achieve the ultimate goal of treating tumors. Currently, immune checkpoint inhibitors are mainly monoclonal antibodies, while researchers are also trying to develop small molecule inhibitors of immune checkpoints.

Creative Biolabs has a wealth of knowledge and experience in premade antibody library screening. We would be happy to share with you our knowledge and experience in premade phage displayed human antibody library construction and antibody discovery for immunotherapy.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: